Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
Go back to Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 289.18 +2.77 (0.97%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $286.41 | 52 Week High | $109.10 | |||
| Open | $290.89 | 52 Week Low | $31.38 | |||
| Day High | $291.95 | P/E | N/A | |||
| Day Low | $285.26 | EPS | $-1.45 | |||
| Volume | 728,445 | |||||
